The cumulative and annual incidence of developing subretinal or vitreous hemorrhage is significantly higher in patients with neovascular AMD who are taking daily aspirin, clopidogrel or warfarin compared to patients not taking these agents. Use of these medications poses a significantly greater odds ratio for developing intraocular hemorrhage than other possible risk factors including age, gender, diabetes, hypertension and bilateral neovascular AMD. Design: Retrospective, cross-sectional study in a tertiary University setting.
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Summary Statement
The cumulative and annual incidence of developing subretinal or vitreous hemorrhage is significantly higher in patients with neovascular AMD who are taking daily aspirin, clopidogrel or warfarin compared to patients not taking these agents. Use of these medications poses a significantly greater odds ratio for developing intraocular hemorrhage than other possible risk factors including age, gender, diabetes, hypertension and bilateral neovascular AMD. 4 those taking daily AP/ACs, whereas age was a significant association in those not taking daily AP/AC agents.
Conclusions: All three daily AP/AC types were significantly associated with an increased risk of the development intraocular hemorrhage in patients with neovascular AMD, whereas gender, hypertension and diabetes were not. Age was not significantly associated with hemorrhage in patients taking daily AP/AC agents whereas the presence of bilateral neovascular AMD was. These findings indicate that the AP/AC use may predispose neovascular AMD patients to intraocular hemorrhage more so than age and duration of disease alone. While the risk that discontinuing these medicines would pose to the patients' health may be too great to justify, ensuring that an appropriate medication dosage is maintained should be a priority within this patient population.
Introduction
The percentage of Americans over the age of 60 years continues to rise, from 16.2% in 2000 to 16.6% in 2006. 1, 2 Life expectancy has also risen steadily to an average of 80.4
years for women and 75.2 years for men. 3 However with increasing age, the prevalence of chronic diseases such as coronary artery disease, atherosclerosis and hypertension is also increasing, as is the use of medications designed to decrease mortality, such as antiplatelet (AP) and anticoagulant (AC) agents. [4] [5] [6] Ophthalmologists have also become increasingly aware of potential problems associated with the use of these medications, including hemorrhagic complications, occurring in association with a variety of multispecialty surgical procedures, [7] [8] [9] [10] [11] including vitrectomy surgery and intravitreal injections. [12] [13] There is also evidence that patients with age-related macular degeneration (AMD) who are taking AP or AC medications may be at increased risk for hemorrhagic complications including severe submacular or vitreous hemorrhage associated with choroidal neovascularization (CNV). When hemorrhage enters the subretinal space anterior to Bruch's membrane, it causes photoreceptor destruction secondary to iron toxicity, blockage of nutrient diffusion and clot retraction, disciform scar formation, and may lead to permanent visual loss. [14] [15] [16] [17] [18] Surgical management of this situation has resulted in variable outcomes, but is generally associated with a poor visual prognosis and a high rate of surgery-associated complications. [19] [20] [21] [22] Given that the number of Americans with AMD is expected to grow to more than 12 million by the year 2020, 23 and the prevalence of AP and AC usage is also likely to rise with an increasing elderly population, the question of whether these agents are independently associated with an 
Materials and Methods
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Results
From the 256 charts identified, one hundred and ninety-five patients met entry criteria, and were included in this study. Sixty-one charts were excluded for the following Baseline factors which were similar between patients taking or not taking AP/AC agents included median follow-up (28.0 and 21.5 months, p=0.10), age, gender, presence of hypertension, and presence of bilateral neovascular disease. However, there were significantly more diabetic patients taking AP/ACs compared to those not taking them (Table 1) .
Ninety-one patients (46.6%) had an occurrence of intraocular hemorrhage over the 6.08 year study period, meaning that among patients with neovascular AMD, the annual incidence was 0.14%. Among patients taking daily AP/AC, the cumulative incidence (61/96, 63.5%) and annual incidence (0.10%) of concurrent intraocular hemorrhage was significantly greater compared to patients not taking them (29/99, 29.2% and 0.04%, respectively, p<0.0001). In addition, hemorrhage incidence density was 0.022 and 0.013 per patient-month, for those taking or not taking AP/AC respectively. Fourteen of 18 (77%) patients taking more than one daily AP/AC had occurrence of intraocular hemorrhage. Multivariate logistic regression analysis demonstrated that AP/AC usage, age and presence of bilateral neovascular AMD were independent risk factors for 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   9 hemorrhage and had significant odds ratios (Table 2) . Seven patients had an occurrence of massive vitreoretinal hemorrhage and 6 of these patients were on one or more AP/AC therapies, implying that the annual incidence of combined subretinal and vitreous hemorrhage was 0.009% in patients using daily AP/ACs and 0.001% in patients not taking them.
Discussion
The overall cumulative incidence, annual incidence and incidence density of intraocular hemorrhage in patients with neovascular AMD is significantly higher in those taking daily oral AP/AC medications. Although the population in this study is one already at risk for ocular hemorrhage by having neovascular AMD, 24 the overall cumulative (63.5%) and annual incidence (0.10%) of hemorrhage is much less compared to prior reports of major or minor systemic hemorrhagic complications (1.2-7% and 2-24%, respectively) in patients receiving long-term anticoagulant therapy. [25] [26] It is also less than in another study which reported that 3% of patients, without ocular disease, who were taking warfarin had incidental retinal hemorrhage on dilated eye examination. 27 The percentage of patients taking AP/ACs is greater in the present study than in a metaanalysis of 68 patients with hemorrhagic complications associated with AMD reported in the literature from 1965 to 1985 in which 19-27% of patients were taking various nonsteroidal anti-inflammatory AP drugs, including aspirin, or ACs. 16 Another report found that 23% of patients with intraocular hemorrhage were taking either AP or AC agents and that AMD patients with massive combined vitreous and subretinal hemorrhages were 11.6 times more likely to be taking warfarin compared to AMD patients presenting with 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 small subretinal hemorrhage, 14 which is comparable to the OR for developing hemorrhage reported in the present study of 10.7 for overall hemorrhage risk. Although no patients were taking clopidogrel, the same previous study described a non-statistically significant odds ratio of 2.1 for aspirin in patients with massive intraocular bleeding, 14 whereas our results indicate significant associations of both aspirin and clopidogrel with intraocular hemorrhage. This underscores the importance for ophthalmologists to inquire about specific AP/AC agents and to communicate with the medical specialist about the patient's AMD status.
This is the first study to report the cumulative incidence and annual incidence of vitreous hemorrhage in patients with neovascular AMD. Six of the 7 patients presenting with these massive hemorrhages were on AP or AC therapy. Although uncommon, the visual consequences of such hemorrhages can be devastating and surgical intervention has limited visual outcomes. [19] [20] [21] [22] Future analysis of other predisposing conditions in addition to AP/AC usage may help identify and develop prophylactic treatment for this
uncommon, yet devastating complication of AMD.
In patients not using daily AP/ACs, increased age was the only associated risk factor for intraocular hemorrhage. Age is a strongly associated risk factor for the development of CNV in patients with AMD 28 and subsequent fibrotic scarring may form a cleavage plane for the development of submacular hemorrhage. [14] [15] [16] 29 The increased risk of hemorrhage associated with patients taking AP/ACs who also had bilateral neovascular AMD in this study may indicate that predisposing systemic reasons for using these agents, such as cardiovascular disease, peripheral arterial disease, deep venous thrombosis, increased serum cholesterol or other factors which were not 11 analyzed may play a role in the pathogenesis of AMD and hemorrhage. The fact that significantly more patients who were taking AP/ACs had diabetes also indicates that this condition may have contributed toward the medical indication for these agents.
An Age-Related Eye Disease Study report reported a higher incidence of central geographic atrophy associated with use of anti-inflammatory medications including aspirin. 30 Our data show that patients taking daily aspirin, the most common antiplatelet agent in this and other major studies 5, 31 were 3.75 times more likely to develop a subretinal hemorrhage than patients not taking it. Although the role of aspirin in decreasing mortality associated with myocardial infarctions and cerebral vascular accidents is well-established, [31] [32] its role as an anti-inflammatory agent and platelet inhibitor in the pathogenesis of AMD remains unclear.
The effect of confounding sources of bias was minimized by using multivariate regression analysis. Misclassification bias was minimized by careful review of medical records and fundus photographs for each subject. Selection bias may have influenced our results since the study was performed at a tertiary university-based referral center, where incidence of intraocular hemorrhage is relatively high, especially since these patients may have been referred for management of their condition.
Another weakness of this study is its retrospective nature; a randomized, prospective cohort study would have greater power to estimate the relative risk of individual AP or AC medications since the cumulative incidence of intraocular hemorrhage is relatively high. However, the reduced risk of myocardial infarction among patients taking aspirin compared to controls in a previous study would ethically preclude randomization of this agent due to excess cardiovascular risk among the placebo group. 33 It would be equally 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 17 
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